Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01802892
First received: November 1, 2012
Last updated: July 3, 2013
Last verified: July 2013
  Purpose

The present study aims to evaluate the impact of 5 days oral administration of ronacaleret 100 miligram (mg) and 400 mg on changes in circulating CD34+ cells, when ronacaleret is followed by the administration of a single dose of plerixafor in healthy human volunteers.

This single centre adaptive design study will be carried out in 2 parts. The part A will evaluate the change in peripheral circulating CD34+ cells in response to two different 5 day regimens of ronacaleret (100 mg or 400 mg once daily), given in conjunction with a single dose of plerixafor (0.24 mg/kilogram [kg]) sub-cutaneously (SC) on the evening of the final days dosing approximately 12 hours before collection of CD34+ cells on day 6. Subjects (5 each) will be assigned to either one of the ronacaleret arms, in an open fashion. Comparisons will be made in the change from baseline to end of treatment peripheral CD34+ cell counts. Part A will be conducted in two cohorts with 5 subjects being enrolled into each of the 2 treatment arms making up the first cohort. Cohort 2 will involve up to 5 further subjects being enrolled into each treatment arm.

The structure of part B will be finalized following a review of data generated in part A.

The total study duration of Part A for each subject including the screening, treatment and follow-up periods will be approximately 7 weeks.


Condition Intervention Phase
Transplantation, Stem Cell
Drug: Ronacaleret 100 mg
Drug: Ronacaleret 400 mg
Drug: Plerixafor
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Mean change from baseline in CD34+ cell counts [ Time Frame: Baseline and upto Day 14 ] [ Designated as safety issue: No ]
    The mean fold change from baseline in the number of circulating CD34+ cells for all treatment arms will be assessed. Samples will be collected at screening, Day 4 and Day 5 (2 hrs post ronacaleret dose), Day 6 (12 hrs and 14 and 16 hrs post plerixafor dose) and Day 14


Secondary Outcome Measures:
  • Spontaneous AE reporting [ Time Frame: Up to 14 days ] [ Designated as safety issue: No ]
    Adverse events (AEs) will be collected from the start of Investigation Product (IP) and until the follow-up visit

  • Clinical laboratory safety data [ Time Frame: Up to 14 days ] [ Designated as safety issue: No ]
    Clinical laboratory tests will include hematology, clinical chemistry and urinalysis

  • Measure of vital signs to access safety and tolerability [ Time Frame: Up to 14 days ] [ Designated as safety issue: No ]
    Vital sign measurements will include systolic and diastolic blood pressure and pulse rate. Subjects should have been in a supine or semi-supine (recumbent) position for at least 5 minutes prior to taking measurements

  • PTH responses [ Time Frame: Up to 6 days ] [ Designated as safety issue: No ]
    Parathyroid hormone (PTH) has been shown to stimulate osteoblasts and osteoclasts and also associated with increased numbers of circulating CD34+ve cells

  • Quantification of the number of stem cells [ Time Frame: Part B will be detailed in an amendment to the protocol following a data review of part A ] [ Designated as safety issue: No ]
    The number of stem cells from the various hematopoietic lineages through colony forming unit assays in Part B of the study


Enrollment: 24
Study Start Date: November 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ronacaleret 100 mg
Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
Drug: Ronacaleret 100 mg
Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
Drug: Plerixafor
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Experimental: Ronacaleret 400 mg
Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
Drug: Ronacaleret 400 mg
Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
Drug: Plerixafor
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A male or female between 18 and 65 years of age (inclusive).
  • Healthy as determined by a physician, based on a medical evaluation and with an estimated Glomerular Filtration Rate (GFR) of >=60 mL/min /1.73 m^2 using the four variable Modification of Diet in Renal Disease (MDRD) equation.
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Female of non-child bearing potential, or female subjects and male subjects with female partners of child-bearing potential willing to use protocol-specified methods of contraception to prevent pregnancy during the study.
  • Body weight of 55 kg or more and body mass index (BMI) of 20.0 to 35.0 kg/m^2 (inclusive).
  • Capable of giving written informed consent.

Exclusion Criteria:

  • A positive pre-study drug/alcohol screen.
  • A positive test for HIV, B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • History of or therapy for osteoporosis
  • Subject has had treatment for any condition relating to the thyroid/parathyroid gland which in the opinion of the investigator may influence the subjects production of PTH
  • Subjects with any contraindications or know allergies to receiving plerixafor
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
  • Subjects taking calcium and/or vitamin D supplements, during or within 2 weeks of study initiation
  • Subjects taking any concomitant medications
  • Specific laboratory abnormalities at screening like Serum calcium (total or albumin-adjusted) outside the central laboratory reference range, PTH outside the normal range, Creatine phosphokinase (CPK) outside the normal range
  • Subjects with abnormal Vitamin D (Vitamin D, 25-Hydroxy) levels may be enroled if repeat lab results, obtained within 14 days of initial screening assessments, are within the normal range
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females.
  • Lactating or pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test at screening or prior to dosing.
  • The subject has participated in a clinical trial within 30 days or 5 half-lives of the IP prior to the first dosing day in the current study.
  • Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01802892

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01802892     History of Changes
Other Study ID Numbers: 116610
Study First Received: November 1, 2012
Last Updated: July 3, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
ronacaleret
parathyroid hormone (PTH)
CD34+cells
calcium sensing receptor antagonist
hematopoietic stem cells
stem cell mobilization
plerixafor
healthy human volunteer, phase Ib

Additional relevant MeSH terms:
JM 3100
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014